Zika virus (ZIKV) isolates are genetically diverse, but belong to two recognized lineages, termed "African" and "Asian." Asian ZIKV infection during pregnancy causes fetal abnormalities including microcephaly. Developing an effective preventative Zika virus vaccine that protects pregnant women is essential for minimizing fetal abnormalities; at least 18 groups are developing ZIKV vaccines (Hayden, 2016) . The genetic and antigenic variability of many RNA viruses limits the effectiveness of vaccines, and the degree to which immunity against one ZIKV strain could provide protection against another is unknown. Here we show that rhesus macaques infected with East African ZIKV strain MR766 are completely protected from subsequent infection with heterologous Asian ZIKV. MR766 is more genetically divergent from all known Asian ZIKV strains than Asian ZIKV strains are from one another. Therefore, ZIKV strain selection is unlikely to compromise vaccine effectiveness.
Introduction
Zika virus (ZIKV) is an arthropod-borne member of the genus Flavivirus of the Spondweni serocomplex that is currently causing an explosive outbreak of febrile disease in the Americas. Historically, ZIKV existed in relative obscurity with only sporadic confirmed human infections until the end of the last century (Hayes, 2009) . ZIKV is believed to have originated in Africa, where it is maintained in an enzootic cycle that includes unknown vertebrate hosts (nonhuman primates are suspected) and arboreal Aedes mosquitoes (HADDOW et al., 1964; McCrae and Kirya, 1982; Wolfe et al., 2001) . In fact, ZIKV was first isolated from the blood of a sentinel rhesus monkey during yellow fever virus surveillance studies in the Zika forest of Uganda (DICK et al., 1952) . The virus is thought to have spread from East Africa into both West Africa and Asia ~50-100 years ago (Faye et al., 2014) . Beginning in 2007, ZIKV outbreaks were reported in Yap Island of the Federated states of Micronesia (Duffy et al., 2009 ), French Polynesia (Cao-Lormeau et al., 2014 , other Pacific islands (Chang et al., 2016) , and in early 2015, in the state of Rio Grande do Norte in northern Brazil (Zanluca et al., 2015) . Since its introduction into the Americas, ZIKV has spread essentially uncontrolled with at least 39 countries and territories experiencing autochthonous transmission, including the US territory of Puerto Rico (Pan American Health Organization, 2016). Eventually, local spread in the southern United States seems likely. In humans, ZIKV infection typically causes a mild and self-limiting illness known as Zika fever, which often is accompanied by maculopapular rash, headache, and myalgia (Campos et al., 2015; Camacho et al., 2016) . During the current outbreak, a causal relationship between prenatal ZIKV infection and fetal microcephaly, as well as other serious brain anomalies, has been established (Driggers et al., 2016; Mlakar et al., 2016; Rasmussen et al., 2016) . Development and testing of vaccines that elicit protective immune responses among girls and women before pregnancy is a top public health priority (Cohen, 2016) .
The ZIKV genome is an ~11 kb single-stranded, positive sense RNA that contains a single open reading frame.
Once the RNA genome is released into the cytoplasm it is directly translated into a polyprotein precursor. The polyprotein is subsequently glycosylated by cellular glycosyltransferases and cleaved by a combination of viral and host proteases to release three structural (C, prM, and E) and seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) (Sirohi et al., 2016) . The envelope (E) glycoprotein is a target for broadly protective neutralizing antibodies in ZIKV and other flaviviruses and is an attractive candidate immunogen for inclusion in ZIKV vaccines (Dai et al., 2016) . Understanding the breadth of immunity elicited by the envelope glycoprotein and the host selection of viral variants is therefore important for vaccine design.
There are three distinct lineages of ZIKV: West African (Nigerian cluster), East African (MR766 prototype cluster), and Asian . All of the ZIKV strains circulating in the Western hemisphere are Asian lineage. The E amino acid identity among all Asian lineage ZIKVs is >99%, and as a group, these are only ~96% and 97% amino acid identical to representative East African and West African viruses, respectively . It is not known whether the differences between African and Asian lineage ZIKV have any phenotypic impact, e.g., increased transmissibility or pathogenicity. Because human infections with ZIKV have historically been sporadic, and, until recently, limited to small-scale epidemics, neither the disease caused by ZIKV nor the molecular determinants of immunity have been well characterized. Accordingly, we recently developed an animal model for Asian-lineage ZIKV infection in Indian-origin rhesus macaques (Macaca mulatta) (Dudley et al., 2016) , and demonstrated that immune responses elicited by infection with Asian ZIKV completely protect against homologous rechallenge with the same ZIKV strain. While this demonstrated the potency of naturally elicited antiviral immunity, it did not address whether such immunity is broadly protective against heterologous ZIKV strains.
To investigate the breadth of protective ZIKV immunity between heterologous lineages of the virus, we infected three macaques with the African prototype strain of ZIKV, MR766 (DICK et al., 1952) . All three animals exhibited an acute, self-limiting infection similar to those previously observed in macaques infected with Asian ZIKV.
Immune responses against MR766 completely protected all three macaques against reinfection using an Asian ZIKV strain and dose that productively infected 6/6 naïve macaques.
Results

Sequence characterization of African lineage MR766 isolates
We elected to use the African ZIKV strain MR766 as the primary challenge virus since this is the prototypical East African ZIKV used in previous studies. MR766 was derived from the original isolate from the Zika Forest, Uganda (DICK et al., 1952) . Interestingly, GenBank contains records for seven different sequences all called ZIKV prototype strain "MR766" (accession numbers: DQ859059, AY632535, LC002520, KU963573, KU955594, KU720415, HQ234498). Differences among these MR766 sequences have been noted previously (Haddow et al., 2012) , but not extensively characterized. All of the Genbank sequences are 99.7-100.0% nucleotide identical to one another within the polyprotein coding sequence, with the exception of DQ859059. Others have shown that the sequence of DQ859059 matches a mosquito-derived sequence unrelated to MR766 (Loman, 2016) . This sequence should be considered a database error and not used as the prototype for any future MR766 analyses.
The most obvious difference between the Genbank MR766 sequences is a four amino acid sequence in the '150 loop' of the E protein that contains a potential N-linked glycosylation site (Dai et al., 2016) that is absent from some of the GenBank reference sequences. The '150 loop' is also absent from other flaviviruses (Dai et al., 2016) . We explored this deletion in greater detail by deep sequencing three MR766 isolates, Zika virus/R.macaque-tc/UGA/1947/MR766-3329 (hereafter referred to as challenge stock, or abbreviated Chal Stk in figures), WRCEVA, and CDC (see Table 1 for passage history). Figure 1A shows amino acid sites in E that differ between the MR766 Genbank sequences and deep sequenced MR766 strains. The deletion was present in between 80.0% and 100.0% of sequencing reads from the three deep sequenced isolates. 85.7% of reads in the stock used to infect the animals in this study (i.e., 'Chal Stk' in Figure 1A ) contained the deletion. Neither of the other sites predicted to have amino acid variability among Genbank MR766 isolates in E differ in any of the three isolates examined in this study.
Including the in-frame four-amino-acid deletion, MR766 is ~96% amino acid identical in E to Asian ZIKV isolates ( Figure 1B) . In contrast, Asian ZIKV isolates are more than 99% amino acid identical to one another in envelope, typically differing by only 0-2 amino acids. In other words, the MR766 challenge stock is more genetically divergent from Asian ZIKV than Asian ZIKV strains are from one another. Therefore, we hypothesized that if immunity elicited by infection of macaques with MR766 protects against reinfection with Asian ZIKV infection, immunity elicited by any Asian ZIKV infection should be sufficient to confer complete protection against subsequent Asian ZIKV reinfection.
Primary infection of Indian-origin rhesus macaques with East African Zika virus MR766
To examine the course of primary infection with MR766, we infected Indian-origin rhesus macaques (two males and one female). This group of animals was designated ZIKV-002 to provide consistency with real-time data on these animals that is publicly available at (Zika experimental science team, 2016). Animals were inoculated subcutaneously with either 1x10 4 , 1x10 5 , or 1x10 6 PFU/mL of our challenge stock, consistent with the route and challenge doses of two previously published cohorts (ZIKV-001 and ZIKV-004) of Indian-origin rhesus macaques challenged subcutaneously with Zika virus/H.sapiens-tc/FRA/2013/FrenchPolynesia-01_v1c1, an Asian ZIKV termed 'ZIKV-FP' for the remainder of the manuscript (Dudley et al., 2016) . A study schematic is shown in Figure   2A . All three animals were productively infected with MR766, with detectable plasma viremia one day post inoculation (dpi) in two of the three animals and in all three by two dpi using a qRT-PCR that amplifies MR766 and Study timeline with dates of primary and secondary heterologous ZIKV challenges. Samples were collected daily from 0 to 10 dpi, and then weekly thereafter until secondary challenge (denoted by ticks along the timeline). Challenge stocks were derived from the East African and French Polynesian virus strains detailed above the timeline. B. Plasma viral loads, shown as vRNA copies/mL for each of the macaques challenged with 1 x 10 6 (solid green line), 1x 10 5 (solid orange line), or 1 x 10 4 (solid blue line) PFU/mL of ZIKV MR766 from the date of primary challenge through 10 days post heterologous challenge with Asian ZIKV. For comparison of plasma viral loads between ZIKV strains, solid light grey lines depict the plasma viral load trajectories for animals that were challenged with the same dose of Asian ZIKV FP and then rechallenged with homologous Asian ZIKV FP. C. Oral swab and D. pan urine viral loads.
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In-frame envelope deletion in MR766 stocks is rapidly lost in vivo
Three and six days after infection, vRNA from the animals was reverse transcribed and PCR-amplified using a primer pair that amplifies the E coding region, including the 12nt in-frame deletion in the 150 loop. PCR amplicons were randomly fragmented and deep sequenced. The in-frame deletion was detected in no more than 0.4% of all reads by three days post infection (Figure 3) . This suggests that the minority population in the challenge stock containing an intact 150 loop rapidly outcompeted viruses containing the in-frame deletion. Because the sequence of the intact sequence was identical to the sequence of the minority population of the challenge stock, de novo repair of the deletion by three days post-infection is unlikely.
Robust cellular and humoral immunity to ZIKV
Proliferation of CD8+ and CD4+ T cells, as well as natural killer cells, was observed following ZIKV MR766 challenge (Figure 4A-C) . These responses, peaking six to ten days post challenge, were robust and mirrored the kinetics of proliferation we previously observed in macaques infected with ZIKV-FP. The peak magnitude of proliferation was slightly lower, on average, than observed following ZIKV-FP infection but the small number of macaques in the study makes it impossible to quantify the significance of this observation. Similarly, we detected an increase in the number of antibody-producing plasmablasts in all three animals after MR766 infection ( Figure 4D) . Serum neutralizing antibody responses also were measured by plaque reduction neutralization test (PRNT90), and all animals exhibited neutralizing antibody (nAb) titers ≥20 against both the challenge stock and ZIKV FP seven days prior to rechallenge (Figure 4E ).
Heterologous challenge with Asian ZIKV
To determine if primary infection with East African ZIKV results in protection from heterologous re-challenge with Asian ZIKV, we inoculated the ZIKV-002 animals with 1 x 10 4 PFU/mL of ZIKV-FP at 70 dpi (10 weeks after primary challenge). This dose was chosen based on successful infection of 6/6 animals from multiple cohorts challenged with this dose to date ( (Dudley et al., 2016) and zika.labkey.com). Viral RNA was undetectable in plasma ( Figure 2B) , saliva (Figure 2C) , and urine (Figure 2D ) at all timepoints through 10 days post re-challenge.
Discussion
Here we describe the first evidence demonstrating that protective immunity resulting from natural ZIKV infection confers protection against reinfection with a heterologous strain of the virus. These findings have potential implications for vaccine development and implementation. Although ZIKV immunology is still in its infancy, we Figure 1A are shown. There were two additional nonsynonymous variants at greater than 5% in animal 562876 at day 3, and the frequency of the amino acid variants from the other animals and time points are shown below each sample. The gray ellipses above the sequences represent the five distinct regions of the Env protein {27158114}. hypothesize that, similar to DENV, nAbs are a critical component of the protective immune response (Guzman et al., 2007; SABIN, 1952) . However, unlike DENV where individuals are at increased risk of symptomatic infection and severe disease upon subsequent heterologous infection, primary ZIKV infection was protective against heterologous rechallenge (though DENV serotypes are more genetically dissimilar to each other than East African and Asian ZIKV). It should be noted that with DENV, cross-serotype protection against symptomatic infection has been observed for up to two years after primary infection, after which point individuals were at greater risk of severe disease (Anderson et al., 2014; Reich et al., 2013; Montoya et al., 2013) , because cross-serotype-reactive antibodies are believed to decay to sub-neutralizing levels that bind DENV without neutralization. Therefore, further work is needed (both experimental and epidemiological) to understand the duration of protective ZIKV immunity after natural infection. Moreover, our study is limited because re-challenges were performed at only a single timepoint; we do not know how soon after primary infection protective immune responses emerge, or for how long they might endure.
Incidental to the primary observation of protective heterologous ZIKV immunity, we also demonstrated that selection appears to favor maintenance of four amino acids that are deleted in the majority of viral sequences in the challenge stock. It is interesting to note that this region contains a putative N-linked glycosylation site (E 154 ), leading us to speculate that this might be consequential for in vivo replication. Flaviviruses contain several putative N-linked glycosylation sites (N-X-S/T) in the E and NS1 proteins. The glycosylation pattern on the viral envelope protein varies among flaviviruses and even among strains of the same virus (Kaufmann and Rossmann, 2011) .
Some, but not all, African ZIKV strains contain a putative E glycosylation site at E 154 (Haddow et al., 2012) . This is also true of West Nile virus (WNV) E 154 . N-linked glycosylation plays an important role in both the assembly and the infectivity of many viruses (Courageot et al., 2000; Lin et al., 2003; Schlesinger et al., 1985; Tassaneetrithep et al., 2003) . For WNV, E protein glycosylation can influence virus infectivity (Hanna et al., 2005) . Deglycosylation of both E and NS1 proteins of WNV completely attenuated neuroinvasiveness and induced protective immunity in the murine model with low doses of virus (Whiteman et al., 2010) . It has been hypothesized that extensive mouse brain or cell culture passage could lead to the deletion of the potential glycosylation site (Chambers et al., 1998) ; therefore it is important to note that the African ZIKV strains analyzed here all underwent extensive mouse brain passage. Consequently, it will be important to sequence low passage, geographically distinct strains to confirm whether or not this glycosylation site polymorphism is an artifact of passage history or if it is representative of circulating strains. However, the fact that the deletion was likely selected against in vivo supports the hypothesis that passage history has influenced glycosylation sites in the African prototype strain and suggests that preservation of this glycosylation site may be important for efficient replication in primates.
These results have important implications for vaccine design and testing. MR766 is more genetically dissimilar to Asian lineage ZIKV isolates than any two Asian lineage ZIKV isolates are from one another. Unlike vaccines for other RNA viruses where immunogen selection is critical, our results suggest that protective immunity elicited against any Asian ZIKV should be sufficient to confer broad protection against all Asian ZIKV strains. Together with our previous results, demonstrating that previous Asian-lineage ZIKV infection protects macaques from homologous rechallenge, the results shown here suggest that immunity elicited by a single ZIKV antigen may provide cross-protective immunity against a multitude of ZIKV strains. ZIKV FP) were used for comparison; details on these animals are available in (Dudley et al., 2016) .
Viruses. ZIKV prototype strain MR766 (referred to as CDC) was obtained from Brandy Russell (CDC, Ft. Collins, CO) and was originally isolated from a sentinel rhesus monkey in 1947 from the Zika Forest, Entebbe, Uganda and passaged 149 times through suckling mouse brains and twice on Vero cells. ZIKV French Polynesian strain (ZIKV FP) was obtained from Xavier de Lamballerie (European Virus Archive, Marseille, France). It was originally isolated from a 51-year old female in France after travel to French Polynesia in 2013 and passaged a single time on Vero cells. Challenge virus stocks were prepared by inoculation onto a confluent monolayer of C6/36 mosquito cells. A single, clarified harvest of each virus, with titers of 5.9 x 10 6 PFU/mL (3.9 x 10 9 vRNA copies/mL) and
1.26 x 10 6 PFU/mL (1.43 x 10 9 vRNA copies/mL) for Zika virus/R.macaque-tc/UGA/1947/MR766-3329 (referred to as challenge stock) and ZIKV FP, respectively, were used for challenges. An additional isolate of ZIKV prototype strain MR766 with 150 suckling mouse brain passages and a single round of amplification on Vero cells was obtained from Robert Tesh (WRCEVA, Galveston, TX). After receipt, this virus also was amplified on C6/36 cells to produce stock virus (referred to as WRCEVA). See Table 1 for a full description of MR766 viruses.
Primary challenge. ZIKV MR766 challenge stock was thawed, diluted with PBS to the appropriate concentration for each challenge, and loaded into a 1mL syringe maintained on ice until challenge. For primary challenges, each of three, Indian-origin rhesus macaques was anesthetized and inoculated with 1mL subcutaneously over the cranial dorsum with either 1x10 4 , 1x10 5 , or 1x10 6 PFU/mL of challenge stock. All animals were closely monitored by veterinary and animal care staff for adverse reactions and signs of disease. Animals were examined, and blood, pan urine, and oral swabs were collected from each animal daily from one through ten days post inoculation (dpi) and then weekly thereafter through 28 dpi. After 28 dpi, animals were rested for six weeks prior to secondary/heterologous challenge. Baseline sampling prior to secondary challenge occurred 56, 63, and 67 days post primary challenge.
Secondary/heterologous challenge. Seventy days after primary challenge, ZIKV FP was thawed and diluted with PBS to 1 x 10 4 PFU/mL, loaded into a 1mL syringe and maintained on ice until challenge. Each animal was anesthetized and inoculated with 1mL subcutaneously over the cranial dorsum with 1x10 4 PFU/mL ZIKV FP.
Animals were closely monitored by veterinary and animal care staff for adverse reactions and signs of disease.
As described previously, animals were examined, and blood, urine, and saliva were collected from each animal daily from one through ten dpi and then weekly thereafter through 28 dpi.
Plaque reduction neutralization test (PRNT90).
Macaque serum samples were screened for ZIKV neutralizing antibody utilizing a plaque reduction neutralization test (PRNT). Endpoint titrations of reactive sera, utilizing a 90% cutoff (PRNT90) were performed as described (Lindsey et al., 1976) against ZIKV FP and challenge stock MR766.
Viral RNA isolation. Plasma was isolated from EDTA-anticoagulated whole blood collected the same day by
Ficoll density centrifugation at 1860 rcf for 30 minutes. Plasma was removed to a clean 15mL conical tube and centrifuged at 670 rcf for an additional eight minutes to remove residual cells. Urine was opportunistically collected from a pan beneath each animal's cage and centrifuged at 500 rcf for five minutes to remove cells and debris.
Saliva was collected using sterile oral swabs run under the tongue while animals were anesthetized. Swabs were placed in viral transport media (tissue culture medium 199 supplemented with 0.5% FBS and 1% antibiotic/antimycotic) for 60-90 minutes, then vortexed vigorously and centrifuged at 500 rcf for five minutes. Prior Figure 1) .
Deep sequencing.
A vial of the same ZIKV MR766 stock used for primary challenge (i.e., challenge stock), a vial of the CDC MR766 stock, and a vial of the WRCEVA MR766 stock were each deep sequenced by preparing libraries of fragmented double-stranded cDNA using methods similar to those previously described (Lauck et al., 2013) . Briefly, the sample was centrifuged at 5000 rcf for five minutes. Figure 2 .
Comparison of East African ZIKV MR766 and Asian Zika virus isolates. Full-length Asian-lineage Zika virus
sequences available in NCBI Genbank as of June 8, 2016 were copied into Geneious Pro 9.1.2 (Biomatters, Ltd., Auckland, New Zealand). The amino acid sequence of E was obtained from these sequences, as well as the consensus sequence from MR766 challenge stocks, by conceptual translation. These amino acid sequences were aligned with MUSCLE (Edgar, 2004) as implemented in Geneious Pro 9.1.2 using default parameters.
Immunophenotyping. Numbers of activated and proliferating NK cells were quantified as described previously (Pomplun et al., 2015) . For each timepoint analyzed, 100 μL of EDTA-anticoagulated whole blood samples were incubated at room temperature for 15 minutes with an antibody master mix described in detail in (Dudley et al., 2016) . Red blood cells were lysed (BD Pharm Lyse, BD Biosciences, San Jose, CA), washed twice, and then fixed with 2% paraformaldehyde for 15 minutes. After fixation, cells were washed and permeabilized using Bulk Permeabilization Reagent (Life Technologies, Madison, WI) and stained with Ki-67 (clone B56, Alexa Fluor 647 conjugate) for 15 minutes. After staining, cells were washed again and resuspended in 2% paraformaldehyde until use in flow cytometry (BD LSRII Flow Cytometer, BD Biosciences, San Jose, CA). Flow cytometry data were analysed using FlowJo v. 9.9.3 (TreeStar, Ashland, OR).
PBMC processing. Fresh PBMC were isolated by Ficoll gradient as described in vRNA isolation. PBMC were collected into R10 media (Hyclone, Logan, UT) and centrifuged at 670 rcf for five minutes, treated with ACK (Grand Island, NY) to removed residual RBC, washed twice more with R10 media, and centrifuged again. R10 was removed and cells were resuspended in Cryostor CS5 media (BioLife Solutions, Bothell, WA), and frozen (1°C/ minute) down to -80°C storing in liquid nitrogen vapor phase until plasmablast assays were performed.
Plasmablast detection. PBMCs isolated from the three ZIKV-002 macaques were stained with the following panel of fluorescently labeled antibodies (Abs) specific for the following surface markers: CD20 FITC (L27), CD80 PE(L307.4), CD123 PE-Cy7(7G3), CD3 APC-Cy7 (SP34-2), IgG BV605(G18-145) (all from BD Biosciences, San Jose, CA), CD14 AF700 (M5E2), CD11c BV421 (3.9), CD16 BV570 (3G8), CD27 BV650(O323) (all from BioLegend, San Diego, CA), IgD AF647 (polyclonal)(Southern Biotech, Birmingham, AL), and HLA-DR PE-TxRed (TÜ36) (Invitrogen, Carlsbad, CA). LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Carlsbad, CA) was used to discriminate live cells. Briefly, cells were resuspended in 1X PBS/1%BSA and stained with the full panel of surface Abs for 30 min in the dark at 4°C, washed once with 1X PBS, stained for 30 min with LIVE/ DEAD Fixable Aqua Dead Cell Stain Kit in the dark at 4°C, washed once with 1X PBS, washed again with 1X PBS/1%BSA, and resuspended in 2% PFA Solution. Stained PBMCs were acquired on a LSRII Flow Analyzer (BD Biosciences, San Jose, CA) and the data was analyzed using FlowJo software v9.7.6 (TreeStar, Ashland, OR). Plasmablasts were defined similarly to the method previously described (Silveira et al., 2015) excluding lineage cells (CD14+, CD16+, CD3+, CD20+, CD11c+, CD123+), and selecting CD80+ and HLA-DR+ cells (known to be expressed on rhesus plasmablasts and their human counterpart (Wrammert et al., 2008) . 
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